Sofinnova Partners, a France-based European venture capital firm in life sciences, has appointed David Evans as partner. He will invest as part of Sofinnova’s Crossover Strategy, its late stage private and public investment fund. The appointment also reinforces Sofinnova’s senior partner presence in London as the firm continues to scale its growth strategy.
Evans, a physician-scientist with deep pharma and drug development expertise, joins from the Roche Venture Fund, where he most recently served as senior investment director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing.
“[Evans] is exactly the kind of investor we look for at Sofinnova – exceptional scientific grounding, real-world clinical experience, and a strong investment instinct built over years at the frontier of healthcare,” said Antoine Papiernik, chairman and managing partner. “His appointment reflects our continued commitment to building a world-class team in the UK and across Europe, and we are delighted to welcome him to the partnership.”
